Skip to content

Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve

Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve (EASE-IT) A Two-armed Registry

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02127580
Acronym
EASE-IT
Enrollment
200
Registered
2014-04-30
Start date
2014-04-30
Completion date
2016-05-31
Last updated
2018-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis

Keywords

THV, BAV, pre-dilation, Aortic valve stenosis

Brief summary

There is limited experience for the balloon expandable THV (transcatheter heart valve) on the need for predilation (ballon aortic valvuloplasty, BAV). Therefore we aim to verify results of a small case series published by Wendler et. al. to examine hard endpoints such as the incidence of cerebrovascular complications, paravalvular leakage and operative outcomes in a multicenter registry. We aim to compare the implantation of balloon expandable transcatheter heart valves with or without predilation with respect to procedural outcomes (VARC2).

Detailed description

Prior to the deployment of transcatheter heart valves (THV), balloon aortic valvuloplasty (BAV) is usually performed under rapid right ventricular pacing (burst \>180 bpm) with the induction of a functional cardiac arrest for up to 30 seconds. Aortic valve predilation is aiming at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects, such as: * Functional cardiac arrest induced by rapid pacing leads to transient coronary, cerebral, and renal ischemia. * In patients with a reduced left ventricular ejection fraction (LVEF), prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS). Both are associated with a high periprocedural mortality. * BAV has been identified as a major source of thrombotic and valvular material and increases the risk for coronary obstruction with subsequent myocardial infarction and stroke. * The local trauma in the left-ventricular outflow tract caused by BAV may potentially contribute to aortic root rupture.

Interventions

PROCEDUREBAV
PROCEDUREwithout BAV

Sponsors

Institut für Pharmakologie und Präventive Medizin
Lead SponsorNETWORK

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with an indication for TAVI as to the Edwards THV IFU * Eligible for TABI with AND without BAV * Signed informed consent

Exclusion criteria

* Logistic EuroSCORE I \>50% * Mitral or tricuspid valvular insufficiency (\> grade II) * Previous aortic valve replacement * Uncontrolled atrial fibrillation * Left ventricular or atrial thrombus by echocardiography * Recent cerebrovascular event (within the last 3 months) * High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)

Design outcomes

Primary

MeasureTime frameDescription
VARC2 criteria3 monthscomparison of the implantation of balloon expandable transcatheter heart valves with or without predilation with respect to procedural outcomes (VARC2).

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026